The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship ...

New research links atopic dermatitis to S1P signalling pathways driving inflammation. Learn how this could shape future ...

Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of ...

Apogee Therapeutics shares rally as Phase 2 APEX data show durable atopic dermatitis control with 3- or 6-month dosing.

As the 2026 American Academy of Dermatology (AAD) annual meeting approaches, MedPage Today is offering a preview of an ...

The most common concerns include which foods might cause or trigger atopic dermatitis, when to introduce solid foods, and ...

A newly identified brain–immune connection suggests stress may directly amplify skin inflammation through targeted cellular ...

A topic dermatitis is a chronic condition that tends to rear its itchy head during certain periods before subsiding — for months, possibly, or even years. It particularly affects the insides of the ...

Atopic dermatitis in childhood is not associated with increased early markers of cardiovascular risk, a study finds.

Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to ...

An experimental treatment for eczema from Apogee Therapeutics induced skin and itch relief comparable to current, widely used ...

Repeated-measures modeling found no consistent links between active atopic dermatitis and BMI, blood pressure, lipid profiles ...